Lv1
20 积分 2022-03-04 加入
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
3天前
已完结
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
1个月前
已完结
Novel insights into lipoprotein(a): News from Atherosclerosis
1个月前
已完结
Lipoprotein(a) and its Significance in Cardiovascular Disease
1个月前
已完结
Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
2个月前
已完结
Can EGFR be a therapeutic target in breast cancer?
2个月前
已完结
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial
2个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3个月前
已完结
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
4个月前
已完结
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
4个月前
已完结
皖公网安备34019202002308
